ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 270 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q2 2024. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $254,820 | -74.5% | 6,200 | -71.0% | 0.02% | -65.4% |
| Q1 2024 | $998,606 | +326.2% | 21,388 | +336.5% | 0.05% | +225.0% |
| Q4 2023 | $234,318 | +6.1% | 4,900 | +2.3% | 0.02% | +14.3% |
| Q2 2023 | $220,870 | -12.7% | 4,788 | -21.8% | 0.01% | +55.6% |
| Q3 2022 | $253,000 | +9.1% | 6,119 | +121.8% | 0.01% | +50.0% |
| Q4 2021 | $232,000 | -37.1% | 2,759 | -28.7% | 0.01% | -45.5% |
| Q2 2021 | $369,000 | +63.3% | 3,869 | +94.9% | 0.01% | +83.3% |
| Q1 2021 | $226,000 | +247.7% | 1,985 | +150.0% | 0.01% | +100.0% |
| Q3 2020 | $65,000 | -90.0% | 794 | -90.5% | 0.00% | -91.7% |
| Q2 2020 | $651,000 | +425.0% | 8,322 | +197.2% | 0.04% | +350.0% |
| Q1 2020 | $124,000 | +1277.8% | 2,800 | +2070.5% | 0.01% | +700.0% |
| Q1 2019 | $9,000 | -98.2% | 129 | -98.4% | 0.00% | -97.9% |
| Q2 2017 | $497,000 | +163.0% | 8,000 | +167.3% | 0.05% | +80.8% |
| Q1 2016 | $189,000 | – | 2,993 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 110,000 | $12,340,000 | 5.16% |
| Iguana Healthcare Management, LLC | 115,000 | $12,901,000 | 4.24% |
| WEATHERBIE CAPITAL, LLC | 206,559 | $23,172,000 | 2.72% |
| Cormorant Asset Management, LP | 109,500 | $12,284,000 | 1.47% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 1,111,566 | $124,695,000 | 1.25% |
| Visium Asset Management, LP | 629,934 | $70,665,000 | 1.06% |
| Rock Springs Capital Management LP | 105,500 | $11,835,000 | 0.90% |
| Cupps Capital Management, LLC | 53,272 | $5,976,000 | 0.84% |
| ROCKEFELLER FINANCIAL SERVICES INC | 289,907 | $32,521,000 | 0.63% |
| Lisanti Capital Growth, LLC | 4,385 | $492,000 | 0.52% |